558 related articles for article (PubMed ID: 33559102)
21. Caregiver-reported outcomes with real-world use of cannabidiol in Lennox-Gastaut syndrome and Dravet syndrome from the BECOME survey.
Berg AT; Dixon-Salazar T; Meskis MA; Danese SR; Le NMD; Perry MS
Epilepsy Res; 2024 Feb; 200():107280. PubMed ID: 38183688
[TBL] [Abstract][Full Text] [Related]
22. The role of cannabinoids in epilepsy treatment: a critical review of efficacy results from clinical trials.
Nabbout R; Thiele EA
Epileptic Disord; 2020 Jan; 22(S1):23-28. PubMed ID: 31916540
[TBL] [Abstract][Full Text] [Related]
23. Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain.
García-Peñas JJ; Gil Nagel-Rein A; Sánchez-Carpintero R; Villanueva-Haba V
Rev Neurol; 2021 Sep; 73(S01):S1-S8. PubMed ID: 34486101
[TBL] [Abstract][Full Text] [Related]
24. Epilepsy and cannabidiol: a guide to treatment.
Arzimanoglou A; Brandl U; Cross JH; Gil-Nagel A; Lagae L; Landmark CJ; Specchio N; Nabbout R; Thiele EA; Gubbay O; The Cannabinoids International Experts Panel ;
Epileptic Disord; 2020 Feb; 22(1):1-14. PubMed ID: 32096470
[TBL] [Abstract][Full Text] [Related]
25. Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials.
Devinsky O; Thiele EA; Wright S; Checketts D; Morrison G; Dunayevich E; Knappertz V
Acta Neurol Scand; 2020 Dec; 142(6):531-540. PubMed ID: 32592183
[TBL] [Abstract][Full Text] [Related]
26. Caregivers' Perspectives on the Impact of Cannabidiol (CBD) Treatment for Dravet and Lennox-Gastaut Syndromes: A Multinational Qualitative Study.
Marshall J; Skrobanski H; Moore-Ramdin L; Kornalska K; Swinburn P; Bowditch S
J Child Neurol; 2023 May; 38(6-7):394-406. PubMed ID: 37455396
[TBL] [Abstract][Full Text] [Related]
27. Cannabinoids in treatment-resistant epilepsy: A review.
O'Connell BK; Gloss D; Devinsky O
Epilepsy Behav; 2017 May; 70(Pt B):341-348. PubMed ID: 28188044
[TBL] [Abstract][Full Text] [Related]
28. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.
Talwar A; Estes E; Aparasu R; Reddy DS
Exp Neurol; 2023 Jan; 359():114238. PubMed ID: 36206805
[TBL] [Abstract][Full Text] [Related]
29. Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy.
Samanta D
Pediatr Neurol; 2019 Jul; 96():24-29. PubMed ID: 31053391
[TBL] [Abstract][Full Text] [Related]
30. Cannabidiol use in patients with Dravet syndrome and Lennox-Gastaut syndrome: experts' opinions using a nominal group technique (NGT) approach.
Bonanni P; Ragona F; Fusco C; Gambardella A; Operto FF; Parmeggiani L; Sartori S; Specchio N
Expert Opin Pharmacother; 2023 Apr; 24(5):655-663. PubMed ID: 37021712
[TBL] [Abstract][Full Text] [Related]
31. Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.
Chen JW; Borgelt LM; Blackmer AB
Ann Pharmacother; 2019 Jun; 53(6):603-611. PubMed ID: 30616356
[TBL] [Abstract][Full Text] [Related]
32. Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome.
Nabbout R; Arzimanoglou A; Auvin S; Berquin P; Desurkar A; Fuller D; Nortvedt C; Pulitano P; Rosati A; Soto V; Villanueva V; Cross JH
Seizure; 2023 Aug; 110():78-85. PubMed ID: 37331197
[TBL] [Abstract][Full Text] [Related]
33. Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs.
Patsalos PN; Szaflarski JP; Gidal B; VanLandingham K; Critchley D; Morrison G
Epilepsia; 2020 Sep; 61(9):1854-1868. PubMed ID: 32918835
[TBL] [Abstract][Full Text] [Related]
34. Long-term efficacy and safety of cannabidiol (CBD) in children with treatment-resistant epilepsy: Results from a state-based expanded access program.
Park YD; Linder DF; Pope J; Flamini JR; Moretz K; Diamond MP; Long SA
Epilepsy Behav; 2020 Nov; 112():107474. PubMed ID: 33181893
[TBL] [Abstract][Full Text] [Related]
35. Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.
Silvinato A; Floriano I; Bernardo WM
Rev Assoc Med Bras (1992); 2022; 68(10):1345-1357. PubMed ID: 36417631
[TBL] [Abstract][Full Text] [Related]
36. Cannabidiol efficacy and clobazam status: A systematic review and meta-analysis.
Lattanzi S; Trinka E; Striano P; Zaccara G; Del Giovane C; Nardone R; Silvestrini M; Brigo F
Epilepsia; 2020 Jun; 61(6):1090-1098. PubMed ID: 32452532
[TBL] [Abstract][Full Text] [Related]
37. Pharmacology and legal status of cannabidiol.
Brunetti P; Lo Faro AF; Pirani F; Berretta P; Pacifici R; Pichini S; Busardò FP
Ann Ist Super Sanita; 2020; 56(3):285-291. PubMed ID: 32959794
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of six new antiseizure medications for adjunctive treatment of focal epilepsy and epileptic syndrome: A systematic review and network meta-analysis.
Tong J; Ji T; Liu T; Liu J; Chen Y; Li Z; Lu N; Li Q
Epilepsy Behav; 2024 Mar; 152():109653. PubMed ID: 38277848
[TBL] [Abstract][Full Text] [Related]
39. Outcomes from a Spanish Expanded Access Program on cannabidiol treatment in pediatric and adult patients with epilepsy.
Villanueva V; García-Ron A; Smeyers P; Arias E; Soto V; García-Peñas JJ; González-Alguacil E; Sayas D; Serrano-Castro P; Garces M; Hampel K; Tomás M; Lara J; de Toledo M; Barceló I; Aledo-Serrano A; Gil-Nagel A; Iacampo L; Falip M; Saiz-Diaz RA; Gómez-Ibañez A; Sopelana D; Sanchez-Larsen A; López-González FJ
Epilepsy Behav; 2022 Dec; 137(Pt A):108958. PubMed ID: 36327646
[TBL] [Abstract][Full Text] [Related]
40. Cannabinoid therapy in epilepsy.
Billakota S; Devinsky O; Marsh E
Curr Opin Neurol; 2019 Apr; 32(2):220-226. PubMed ID: 30676535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
